Solana (NASDAQ:HSDT) Announces Quarterly Earnings Results

Solana (NASDAQ:HSDT) posted its earnings results on Friday. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.96), FiscalAI reports. The company had revenue of $3.62 million for the quarter, compared to the consensus estimate of $3.40 million. Solana had a negative net margin of 679.54% and a negative return on equity of 104.96%.

Here are the key takeaways from Solana’s conference call:

• Solana Company said first-quarter revenue rose to $3.6 million from just $49,000 a year ago, driven mainly by $3.4 million of staking revenue. Management framed this as early validation of its digital asset treasury strategy.
• The company reported a net loss of $99.8 million, largely due to non-cash markdowns tied to the roughly 33% decline in SOL during the quarter. It also recorded an $89.2 million unrealized loss on digital assets and receivables.
• Management highlighted 6.9% average net staking yield in Q1, above the estimated system-wide average of about 6.0%. They said this outperformance came from validator selection, MEV capture, and active rebalancing.
• The company completed an $8 million strategic equity raise in late April at a price described as about 1.1x NAV, and said part of the proceeds was used to buy SOL at attractive levels. Management called the raise immediately accretive to SOL per share.
• Solana Company is expanding beyond treasury management into advisory services, validator infrastructure, and an AI-powered platform, with initial validator nodes expected to go live in late June. Management also said it completed the divestiture of its medical device business, which should help reduce future costs.

Solana Stock Performance

Shares of HSDT stock traded down $0.09 during mid-day trading on Friday, hitting $2.30. 147,829 shares of the stock traded hands, compared to its average volume of 216,834. Solana has a twelve month low of $1.59 and a twelve month high of $258.50. The firm has a market cap of $126.25 million, a price-to-earnings ratio of 0.00 and a beta of 1.06. The company’s 50-day simple moving average is $2.06 and its 200-day simple moving average is $2.92.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HSDT. B. Riley Financial began coverage on Solana in a report on Thursday, April 23rd. They set a “buy” rating and a $3.00 target price for the company. Maxim Group began coverage on Solana in a report on Monday, April 6th. They set a “buy” rating and a $4.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Solana in a report on Tuesday, April 21st. Finally, Zacks Research raised Solana to a “hold” rating in a report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.50.

Hedge Funds Weigh In On Solana

Several hedge funds have recently modified their holdings of the company. LPL Financial LLC increased its position in shares of Solana by 120.1% during the 4th quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock valued at $1,105,000 after purchasing an additional 208,558 shares during the period. Geode Capital Management LLC acquired a new position in shares of Solana during the 4th quarter valued at $1,006,000. State Street Corp acquired a new position in shares of Solana during the 4th quarter valued at $464,000. Cetera Investment Advisers acquired a new position in shares of Solana during the 4th quarter valued at $347,000. Finally, Marshall Wace LLP acquired a new stake in shares of Solana during the 4th quarter valued at $195,000. 18.63% of the stock is currently owned by institutional investors and hedge funds.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.